ArticleFrontiers in pharmacology2026
Knowledge, attitudes, and practices toward xylometazoline nasal spray use among adults in Saudi Arabia: a cross-sectional survey.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Nasal congestion is a frequent symptom of upper respiratory illnesses. Over-the-counter decongestants such as xylometazoline are widely used, providing rapid relief but prone to misuse. In Saudi Arabia, there is limited evidence of public attitudes, practices, and predictors. This study aimed to assess knowledge, attitudes, and practices toward xylometazoline among adults in Saudi Arabia and to identify sociodemographic predictors of appropriate use. Methods: A cross-sectional survey, conducted between May and July 2025, included adults (≥18 years) residing in Saudi Arabia. A validated questionnaire was used to collect sociodemographic data, xylometazoline use, and assess KAP scores. Descriptive statistics summarized outcomes. Spearman's rho assessed correlations among KAP domains. Predictors of knowledge, attitude, and practice were examined using binary logistic regression, reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Two-sided p < 0.05 was considered statistically significant. Results: A total of 422 individuals participated; 226 (53.6%) were female, and 185 (43.8%) were aged 18-30 years. Xylometazoline use in the past 12 months was reported by 295 (69.9%). Overall, 217 (51.4%) demonstrated good knowledge, 232 (55.0%) held a positive attitude, and only 37 (8.8%) reported good practice, while 187 (44.3%) reported poor practice. Postgraduate education was significantly associated with good knowledge (aOR 2.78, 95% CI 1.42-5.45), while chronic nasal infections with severe dryness were strongly associated with good practice (aOR 6.29, 95% CI 1.72-22.97). Good practice decreased with higher frequency of use (1-3 times/year: aOR 0.37; 4-6: aOR 0.18; >6: aOR 0.05; all p < 0.001). Regional variations in knowledge and attitudes were also observed. Conclusion: Xylometazoline use is highly prevalent in Saudi Arabia, with favorable knowledge and attitudes but suboptimal practices. Younger age and higher education were associated with better knowledge, while female sex and nasal conditions predicted safer practices. Public education and pharmacist-led counseling, particularly on safe duration of use, are essential to close the knowledge-practice gap and reduce misuse.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.